AI generated
Apr 2, 2026, 08:22
Chokri Ben Lamine: Laboratory Findings and Management of Severe Type 3 von Willebrand Disease
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Type 3 VWD equals near‑total absence of vWF, which is the most severe form.
Family – autosomal recessive; think consanguinity.
Phenotype
- Mucocutaneous bleeding (epistaxis, gums, menorrhagia)
- Deep bleeding, such as hemarthrosis and muscle bleeding, results in a clinical picture that mimics hemophilia A.
Labs
- vWF:Ag and activity absent
- Factor VIII very low – less than ten percent.
- aPTT prolonged
- PT normal
Pearl: DDAVP is ineffective because there is no endogenous von Willebrand factor available to release.
Life-threatening bleeding (ICH, GI, major trauma)
- Immediate vWF-containing concentrate (Humate-P, Wilate) high dose
- Target: normalize vWF activity and FVIII rapidly
- Repeat dosing q8-12h based on levels/clinical response
- Add FVIII if levels critically low or delayed response
- ICU-level care plus local hemostatic measures
Non–life-threatening bleeding (epistaxis, menorrhagia, minor procedures)
- vWF-containing concentrate (lower dose / shorter duration)
- Tranexamic acid for mucosal bleeding
- Local measures (pressure, topical TXA, nasal packing, etc.)
Complication: Alloantibodies to vWF lead poor response / anaphylaxis risk change symbols to words ”
Stay updated with Hemostasis Today.
-
Apr 2, 2026, 08:12Heghine Khachatryan: Dementia at the Intersection of Hematology and Hemostasis
-
Apr 2, 2026, 08:03Thomas Pincez: Revised Guidelines Improve Care for Pediatric Immune Thrombocytopenia
-
Apr 2, 2026, 04:47Augustina Isioma Ikusemoro: A Small Antigen with Big Clinical Consequences
-
Apr 2, 2026, 04:28Mohammed Almohammadi: Etiologic Spectrum and Diagnostic Challenges of Hypocellular Marrow Findings
-
Apr 2, 2026, 04:18Emmanuele Kouvousis: Physical Inactivity as a Leading Global Health Risk
-
Apr 2, 2026, 04:03Robert Lufkin: The Misleading Concept of Metabolically Healthy Obesity in Childhood
-
Apr 1, 2026, 23:00Wolfgang Miesbach: What Goes Wrong When Approved Gene Therapies Get Withdrawn?
-
Apr 1, 2026, 22:00Aurelio Maggio: Congratulations to Mariasanta Napolitano on Her 1st Year Leading the Haematology and Rare Disease Uni tat ”V. Cervello” Hospital
-
Apr 1, 2026, 21:21Shubham Misra: CCL2 As a Potential Biomaker for Post-Stroke Seizures, Epileptiform Discharges and Mortality